PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Dupilumab→

Dupilumab PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1190264-60-8
Molecular formula
Not available
Molecular weight
Not available
Drug class
Interleukin-4 Receptor alpha AntagonistAntibodies, Monoclonal
Mechanism of action
Interleukin 4 Receptor alpha Antagonists [MoA]
Indications / reported uses
  • Dermatitis, Atopic
  • adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
  • acute bronchospasm or status asthmaticus
  • adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE)
  • adult patients with prurigo nodularis (PN)

Sources: FDA product labels (openFDA) · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Dupilumab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Dupilumab Permitted Daily Exposure (PDE) report (the Dupilumab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Dupilumab Occupational Exposure Limit (OEL) report (the Dupilumab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.